Aminopyrimidine PI3Kδ Inhibitors With Selectivity and PK Balance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for new PI3K inhibitors that are potent, selective, and well-absorbed drug candidates with favorable pharmacokinetic properties, particularly targeting PI3Kδ, to treat a wide range of disorders including autoimmune diseases, inflammatory diseases, allergic diseases, and cancers, while minimizing side effects and avoiding the blood-brain barrier when necessary.
Innovation Solution
Development of novel substituted aminopyrimidine compounds that act as selective inhibitors of PI3-kinase activity, particularly targeting PI3Kδ, with specific chemical structures defined by Formula (I) and (II), offering potential therapeutic benefits across various disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional PI3K inhibitors are used, then kinase inhibition activity is achieved, but selectivity among different PI3K isoforms deteriorates leading to off-target effects
Solution Approach 1:
The patent applies local quality by designing specific substituent patterns at defined positions on the pyrimidine core structure. Different substituents (R1-R6) are placed at specific locations to create localized interactions with PI3Kδ, enhancing selectivity for this isoform while maintaining inhibition activity. The amino group at position 4 and specific substituents at positions 2, 5, and 6 create a unique molecular fingerprint that selectively binds to PI3Kδ over other isoforms.
Solution Approach 2:
The patent employs parameter changes by systematically varying chemical parameters including substituent types (halogens, alkyl groups, aryl groups), substituent positions, and molecular weight. These parameter modifications allow optimization of the balance between inhibition potency and selectivity, enabling the compounds to achieve high PI3Kδ selectivity while maintaining effective kinase inhibition.
2Reliability
If highly potent PI3K inhibitors are developed, then therapeutic efficacy is improved, but pharmacokinetic properties such as absorption and metabolic stability deteriorate
Solution Approach 1:
The patent applies parameter changes by optimizing molecular weight (keeping it in a favorable range for oral absorption), lipophilicity (through careful selection of hydrophobic and hydrophilic substituents), and metabolic stability (by avoiding labile functional groups). These parameter adjustments ensure that potent inhibitors also possess good pharmacokinetic properties for clinical development.
Solution Approach 2:
The patent extracts or removes problematic functional groups that would compromise pharmacokinetic properties while retaining the core inhibitory structure. By selectively eliminating or modifying labile substituents and optimizing the overall molecular architecture, the compounds achieve both high potency and improved metabolic stability and absorption characteristics.
3Reliability
If PI3K inhibitors are designed to cross the blood-brain barrier, then central nervous system efficacy is improved, but off-target effects in the brain increase
Solution Approach 1:
The patent applies local quality by introducing specific lipophilic substituents at strategic positions to enable blood-brain barrier penetration when CNS efficacy is desired, while maintaining overall molecular selectivity for PI3Kδ. The localized modification of lipophilicity through specific R groups allows controlled CNS penetration without compromising the selective binding to the target isoform.
Solution Approach 2:
The patent employs dynamics by designing compounds where the balance between blood-brain barrier penetration and selectivity can be dynamically adjusted through substituent selection. The same core structure can be tailored for CNS or non-CNS indications by modifying specific substituents, allowing the drug to adapt its distribution profile to the therapeutic need while maintaining PI3Kδ selectivity.
Data Source
AI summary
The invention relates to the preparation and use of new aminopyrimidine derivatives as drug candidates in free form or in pharmaceutically acceptable salt form and formulations thereof for the modulation of a disorder or disease which is mediated by the activity of the PI3K enzymes. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of disorders or diseases, such as disorders of immunity and inflammation in which PI3K enzymes play a role in leukocyte function, and hyperproliferative disorders associated with PI3K activity, including but not restricted to leukemias and solid tumors, in mammals, especially humans.